CA Patent

CA2618255A1 — Itraconazole compositions with improved bioavailability

Assigned to AbbVie Deutschland GmbH and Co KG · Expires 2007-02-15 · 19y expired

What this patent protects

A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35 > .DELTA.Htr (1) (wherein .DELTA.Htr represents the endotherm (J/g) accompanying a transition at about 240~ C). The solid dispersion product shows an improved…

USPTO Abstract

A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35 > .DELTA.Htr (1) (wherein .DELTA.Htr represents the endotherm (J/g) accompanying a transition at about 240~ C). The solid dispersion product shows an improved bioavailability.

Drugs covered by this patent

Patent Metadata

Patent number
CA2618255A1
Jurisdiction
CA
Classification
—
Expires
2007-02-15
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Deutschland GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.